ITRM920681A1 - Complesso di bismuto citrato di ranitidina ed antibiotico, composizione che lo contiene e relativo metodo di produzione ed impiego - Google Patents

Complesso di bismuto citrato di ranitidina ed antibiotico, composizione che lo contiene e relativo metodo di produzione ed impiego

Info

Publication number
ITRM920681A1
ITRM920681A1 IT000681A ITRM920681A ITRM920681A1 IT RM920681 A1 ITRM920681 A1 IT RM920681A1 IT 000681 A IT000681 A IT 000681A IT RM920681 A ITRM920681 A IT RM920681A IT RM920681 A1 ITRM920681 A1 IT RM920681A1
Authority
IT
Italy
Prior art keywords
ritnitine
bismuto
antibiotic
production
composition containing
Prior art date
Application number
IT000681A
Other languages
English (en)
Inventor
Andrew Alexander Mccolm
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ITRM920681A0 publication Critical patent/ITRM920681A0/it
Publication of ITRM920681A1 publication Critical patent/ITRM920681A1/it
Application granted granted Critical
Publication of IT1262993B publication Critical patent/IT1262993B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
ITRM920681A 1991-09-20 1992-09-18 Complesso di bismuto citrato di ranitidina ed antibiotico, composizione che lo contiene e relativo metodo di produzione ed impiego IT1262993B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919120131A GB9120131D0 (en) 1991-09-20 1991-09-20 Medicaments

Publications (3)

Publication Number Publication Date
ITRM920681A0 ITRM920681A0 (it) 1992-09-18
ITRM920681A1 true ITRM920681A1 (it) 1994-03-18
IT1262993B IT1262993B (it) 1996-07-23

Family

ID=10701750

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920681A IT1262993B (it) 1991-09-20 1992-09-18 Complesso di bismuto citrato di ranitidina ed antibiotico, composizione che lo contiene e relativo metodo di produzione ed impiego

Country Status (26)

Country Link
US (3) US5668130A (it)
EP (1) EP0533281B1 (it)
JP (1) JPH0692850A (it)
KR (1) KR100257367B1 (it)
AT (2) ATE228835T1 (it)
BE (1) BE1005808A5 (it)
CA (1) CA2078579A1 (it)
CH (1) CH685372A5 (it)
CY (1) CY2012A (it)
CZ (1) CZ282840B6 (it)
DE (1) DE69232864T2 (it)
ES (1) ES2188582T3 (it)
FR (1) FR2682040B1 (it)
GB (2) GB9120131D0 (it)
HK (1) HK78197A (it)
HU (1) HU211170A9 (it)
IE (1) IE922673A1 (it)
IL (1) IL103213A (it)
IT (1) IT1262993B (it)
MX (1) MX9205313A (it)
NO (1) NO301456B1 (it)
NZ (1) NZ244390A (it)
PT (1) PT533281E (it)
RU (1) RU2116071C1 (it)
SK (1) SK280283B6 (it)
ZA (1) ZA927157B (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005315A1 (en) * 1988-10-31 1990-05-17 Sumitomo Cement Co., Ltd. Antireflection articles, process for their production and coating composition
JPH08506353A (ja) * 1993-06-15 1996-07-09 フアイザー・インコーポレイテツド ウシもしくはブタの細菌感染における免疫刺激剤としてのｈ２−拮抗剤
ATE192932T1 (de) * 1993-09-09 2000-06-15 Takeda Chemical Industries Ltd Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
US5795871A (en) * 1994-04-26 1998-08-18 Nobuhiro Narita Pharmaceutical composition for treatment of non-small cell lung cancer
US6117412A (en) * 1995-01-26 2000-09-12 Nycomed Imaging As Non-cluster type bismuth compounds
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US5900410A (en) * 1996-08-27 1999-05-04 Hartmann; John F. Monotherapy of peptic ulcers and gastritis
DE19709897A1 (de) * 1997-03-11 1998-09-17 Hoechst Ag Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel
US6017950A (en) * 1997-08-05 2000-01-25 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
IT1296980B1 (it) * 1997-12-17 1999-08-03 Istituto Pirri S R L Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
AU3668000A (en) * 1999-04-29 2000-11-17 Russinsky Limited Compounds
CZ20023167A3 (cs) * 2000-02-29 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinu a klaritromycinového meziproduktu, v podstatě prostého oximu a farmaceutický prostředek, který jej obsahuje
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
JP2006520810A (ja) 2003-03-17 2006-09-14 日本たばこ産業株式会社 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same
WO2014049841A1 (ja) 2012-09-28 2014-04-03 参天製薬株式会社 マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
WO2020045807A1 (ko) 2018-08-31 2020-03-05 한국지질자원연구원 비흡수성 항생물질 및 점토광물의 복합체를 포함하는 조성물을 대상에게 경구투여하는 단계를 포함하는 헬리코박터 파일로리의 제균 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB772567A (en) * 1954-05-06 1957-04-17 Siegfried Fischl Preparation of stable, injectable bismuth-containing pharmaceutical compositions and the compositions formed thereby
SG72632A1 (en) * 1985-04-18 2000-05-23 Procter & Gamble Treatment of non-ulcer dyspepsia with bismuth salts
EP0206625B1 (en) * 1985-06-13 1992-09-30 Barry James Dr. Marshall Compositions for the treatment of gastrointestinal disorders
US5256684A (en) * 1985-06-13 1993-10-26 The Procter & Gamble Company Methods and compositions for the treatment of gastrointestinal disorders
US4959384A (en) * 1985-10-24 1990-09-25 Norwich Eaton Pharmaceuticals, Inc. Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
EP0282132B1 (en) * 1987-03-09 1992-09-30 The Procter & Gamble Company Compositions and their use for treating gastrointestinal disorders
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
US5196205A (en) * 1987-10-12 1993-03-23 Borody Thomas J Method for treatment of gastro intestinal disorders
CH679582A5 (it) * 1988-07-18 1992-03-13 Glaxo Group Ltd
FI910088A (fi) * 1990-01-09 1991-07-10 Gist Brocades Nv Oral farmaceutisk komposition.
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
WO1992010302A1 (de) * 1990-12-04 1992-06-25 Mueller Werner Bewässerungsanlage für hallenböden von reithallen, treibhäusern u. dgl.
US5176698A (en) * 1991-01-09 1993-01-05 Scimed Life Systems, Inc. Vented dilatation cathether and method for venting
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions

Also Published As

Publication number Publication date
AT403656B (de) 1998-04-27
MX9205313A (es) 1993-04-01
DE69232864D1 (de) 2003-01-16
US5629297A (en) 1997-05-13
CZ282840B6 (cs) 1997-10-15
GB2259647A (en) 1993-03-24
CY2012A (en) 1998-02-20
NZ244390A (en) 1997-06-24
GB2259647B (en) 1995-11-29
IT1262993B (it) 1996-07-23
PT533281E (pt) 2003-04-30
GB9219749D0 (en) 1992-10-28
EP0533281B1 (en) 2002-12-04
US5674858A (en) 1997-10-07
SK280283B6 (sk) 1999-11-08
NO301456B1 (no) 1997-11-03
IL103213A (en) 2000-02-29
GB9120131D0 (en) 1991-11-06
AU663520B2 (en) 1995-10-12
NO923643L (no) 1993-03-22
ES2188582T3 (es) 2003-07-01
ATE228835T1 (de) 2002-12-15
DE69232864T2 (de) 2003-11-20
BE1005808A5 (fr) 1994-02-01
CA2078579A1 (en) 1993-03-21
EP0533281A1 (en) 1993-03-24
NO923643D0 (no) 1992-09-18
ZA927157B (en) 1993-06-15
IE922673A1 (en) 1993-03-24
FR2682040A1 (fr) 1993-04-09
US5668130A (en) 1997-09-16
KR930005619A (ko) 1993-04-20
CH685372A5 (fr) 1995-06-30
CZ287892A3 (en) 1993-12-15
JPH0692850A (ja) 1994-04-05
ATA186692A (de) 1997-09-15
AU2458492A (en) 1993-03-25
HK78197A (en) 1997-06-20
RU2116071C1 (ru) 1998-07-27
KR100257367B1 (ko) 2000-05-15
ITRM920681A0 (it) 1992-09-18
SK287892A3 (en) 1995-06-07
IL103213A0 (en) 1993-02-21
FR2682040B1 (fr) 1994-10-28
HU211170A9 (en) 1995-11-28

Similar Documents

Publication Publication Date Title
ITRM920681A1 (it) Complesso di bismuto citrato di ranitidina ed antibiotico, composizione che lo contiene e relativo metodo di produzione ed impiego
DE69006628T2 (de) Pharmazeutische Zusammensetzung, enthaltend Loratadin, Ibuprofen und Pseudoephedrin.
DE68918489D1 (de) Herstellung von supraleitenden Oxidfilmen durch eine pre-Sauerstoff-Stickstoffglühbehandlung.
ATE305791T1 (de) Pharmazeutische zubereitungen zur behandlung von magengeschwüren
DK0435333T3 (da) Cephalosporinderivater, fremgangsmåde til fremstilling deraf og antimikrobielt præparat indeholdende derivaterne
DE3685052D1 (de) Linolensaeuren enthaltende pharmazeutische und diaet-zusammensetzungen zur behandlung von gutartiger prostatahypertrophie.
EP0194901A3 (en) Isoprenoidamine derivatives, compositions containing them, their preparation, and their use
ATE66610T1 (de) Primycin enthaltendes kolloidales grundgel, verfahren zu dessen herstellung, dieses grundgel enthaltende pharmazeutische und pharmako- kosmetische kompositionen.
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
DK161384C (da) Pyrazolooe3,4,5-klaaacridinforbindelser og farmaceutiske praeparater indeholdende saadanne forbindelser
IT1229223B (it) Composizioni veterinarie sinergisticamente attive e procedimento per la loro preparazione.
SE8204034D0 (sv) Substituerade pyrrolo (2,1-b)kinazoliner och pyrido(2,1-b)kinazoliner och forfarande for deras framstellning
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
DE69009765T2 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3782661T2 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs.
EP0188373A3 (en) Macrolide derivatives
IT8747852A0 (it) Benzammidi sostituite, procedimento per la loro preparazione e composizioni farmaceutiche che le contengono
IT8720179A0 (it) 2-sulfinil-acetil-1,3-tiazolidine, loro preparazione e composizioni farmaceutiche.
ATE45146T1 (de) Substituierte dihydrochinoloncarbonsaeuren und diese enthaltende antibakterielle zusammensetzungen.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970929